Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Cleveland Biolabs logo — company profile

Cleveland Biolabs

Founded 2003 United States Buffalo, United States 21 employees Post-IPO Equity Total: $111.10M Biotechnology, Health Care

General Information

Company Name Cleveland Biolabs
Founded Year 2003
Location United States Buffalo, United States
Founders / Decision Makers
Team member
Employees 21
Industries Biotechnology, Health Care
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Cleveland Biolabs. To contact Cleveland Biolabs, visit cbiolabs.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Cleveland Biolabs compare?

A PDF of Cleveland Biolabs and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Cleveland Biolabs soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Cleveland Biolabs

Cleveland BioLabs is a Clinical-stage biotechnology company focused on oncology and orphan drug development. Since its establishment in 2003, the company has been dedicated to the research, development, and commercialization of proprietary products targeting the potential treatment of cancer, prevention and treatment of acute radiation syndrome, and counteraction of the toxic effects of radio and chemotherapies for oncology patients. Presently, the company has nine product candidates in its pipeline being developed directly by them and their majority-owned subsidiaries, Incuron, LLC, and Panacela Labs, Inc. The company's focus on critical medical needs and its innovative approach to proprietary product development position it as a key player in the biotechnology and healthcare industries. Recently, Cleveland BioLabs received a significant $14.00M Post-IPO Equity investment on 19 February 2021. This investment reflects the confidence of investors in the potential of the company and its product pipeline. With its headquarters in the United States, Cleveland BioLabs continues to make strides in the development of crucial medical solutions, making it a compelling consideration for potential venture capital investments.

Business keywords: oncology, drug development, clinical-stage, cancer treatment, radiation therapy, chemotherapy, acute radiation syndrome, orphan drugs, defense applications, tissue protection, proprietary products, clinical trials, majority-owned subsidiaries

Funding Rounds & Investors (12)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $14.00M -
19 Feb 2021
Post IPO Equity $3.18M -
01 Jun 2020
Post IPO Equity $10.50M 1
Norma Investment
Norma Investment
16 Aug 2018
Post IPO Equity $25.00M 1
David Davidovich
16 Jul 2015
Post IPO Equity $4.20M -
04 Feb 2015
Post IPO Equity $3.50M -
03 Jul 2014
Post IPO Equity $7.00M -
14 Jan 2014
Post IPO Debt $10.00M 1
Hercules Capital
Hercules Capital
01 Oct 2013
Post IPO Equity $5.00M -
05 Mar 2010
Post IPO Equity $3.73M -
06 Apr 2009

View All 12 Funding Rounds

Cleveland Biolabs Alternatives & Competitors

View All Alternatives
Cleveland Biolabs vs
Panacela Labs
Panacela Labs

Fostering biomedical breakthroughs for oncology and rare diseases through global collaboration

Series B
3 employees
Biotechnology, Health Care
Cleveland Biolabs vs
Arcellx
Arcellx United States

Arcellx is a clinical-stage biotechnology company based in Redwood City, California

Acquired
121 employees
Biopharma, Biotechnology
Cleveland Biolabs vs
Cavion
Cavion

Empowering therapies for cancer and neurologic diseases through pioneering ion channel inhibition

Series A
Biotechnology, Health Care
View all alternatives

FAQ About Cleveland Biolabs

Cleveland BioLabs, Inc. (Nasdaq:CBLI) is a clinical-stage biotechnology company with a focus on oncology and orphan drug development. Since our inception in 2003, we have pursued the research, development and commercialization of proprietary products that have the potential to treat cancer, preve...
Cleveland Biolabs was founded in 2003.
Cleveland Biolabs is headquartered in Buffalo, United States.
Cleveland Biolabs operates in Biotechnology and Health Care. Its work centres on oncology, drug development, clinical-stage and cancer treatment.
Cleveland Biolabs has approximately 21 employees.
Cleveland Biolabs has completed 12 funding rounds, raising a total of $111.10M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Cleveland Biolabs include Panacela Labs, Arcellx, Cavion, Tetralogic Pharmaceuticals, Cascadian Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Cleveland Biolabs and Panacela Labs are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Cleveland Biolabs, https://bouncewatch.com/company/cleveland-biolabs, updated 1 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout